Gd-EOB-DTPA-Enhanced MRI for Detection of Liver Metastases from Colorectal Cancer: A Surgeon’s Perspective!
Author(s) -
Kelly J. Lafaro,
Panayota S. Roumanis,
Aram N. Demirjian,
Chandana Lall,
David K. Imagawa
Publication year - 2013
Publication title -
international journal of hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.734
H-Index - 14
eISSN - 2090-3448
pISSN - 2090-3456
DOI - 10.1155/2013/572307
Subject(s) - medicine , colorectal cancer , magnetic resonance imaging , computed tomographic , radiology , gadoxetic acid , resection , cancer , computed tomography , surgery , gadolinium dtpa
Colorectal cancer affects over one million people worldwide annually, with the liver being the most common site of metastatic spread. Adequate resection of hepatic metastases is the only chance for a cure in a subset of patients, and five-year survival increases to 35% with complete resection. Traditionally, computed tomographic imaging (CT) was utilized for staging and to evaluate metastases in the liver. Recently, the introduction of hepatobiliary contrast-enhanced magnetic resonance imaging (MRI) agents including gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Eovist in the United States, Primovist in Europe, or Gd-EOB-DTPA) has proved to be a sensitive method for detection of hepatic metastases. Accurate detection of liver metastases is critical for staging of colorectal cancer as well as preoperative planning.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom